Partner with Genomic Health on management and treatment decisions for your prostate cancer patients

Guide treatment decisions for your Gleason Score 3+3 and 3+4 patients


Determine the next treatment step for your mCRPC patients who have failed an AR-targeted therapy


† Androgen receptor (AR)-targeted therapies include Erleada™ (apalutamide), Zytiga® (abiraterone), and Xtandi® (enzalutamide).

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.™